Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
72 participants
INTERVENTIONAL
2013-02-28
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects
NCT01461460
A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects
NCT02117830
Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
NCT03012828
A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants
NCT03696459
A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants
NCT03494907
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ANX-188 Therapeutic dose level
IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours
ANX-188 Therapeutic Dose
ANX-188 Supratherapeutic dose
IV administration. 300 mg/kg for one hour followed by 200 mg/kg/hr for five hours
ANX-188 Supratherapeutic dose
Saline
IV administration. Six hour infusion.
Saline
Moxifloxacin
Oral tablet. 400 mg.
Moxifloxacin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ANX-188 Therapeutic Dose
ANX-188 Supratherapeutic dose
Saline
Moxifloxacin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant or lactating females
* Use of prescription drugs, herbals, or over-the-counter medications within 14 days prior to study day -2
* Uncontrolled cardiac arrhythmias, cardiac valve abnormalities, or not in normal sinus rhythm
* Smokers or tobacco product user in the prior 3 months
* Presence of clinically significant illness
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mast Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edwin L Parsley, D.O.
Role: STUDY_DIRECTOR
Mast Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANX-188-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.